Mark Marzinke
Mark Marzinke
Professor, Johns Hopkins University School of Medicine
Verified email at
Cited by
Cited by
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 …
K Choopanya, M Martin, P Suntharasamai, U Sangkum, PA Mock, ...
The Lancet 381 (9883), 2083-2090, 2013
Tenofovir-based preexposure prophylaxis for HIV infection among African women
JM Marrazzo, G Ramjee, BA Richardson, K Gomez, N Mgodi, G Nair, ...
New England Journal of Medicine 372 (6), 509-518, 2015
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women
JM Baeten, T Palanee-Phillips, ER Brown, K Schwartz, LE Soto-Torres, ...
New England Journal of Medicine 375 (22), 2121-2132, 2016
Cabotegravir for HIV prevention in cisgender men and transgender women
RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ...
New England Journal of Medicine 385 (7), 595-608, 2021
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
S Delany-Moretlwe, JP Hughes, P Bock, SG Ouma, P Hunidzarira, ...
The Lancet 399 (10337), 1779-1789, 2022
Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1–serodiscordant couples: a prospective implementation study in Kenya and Uganda
JM Baeten, R Heffron, L Kidoguchi, NR Mugo, E Katabira, EA Bukusi, ...
PLoS medicine 13 (8), e1002099, 2016
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis
M Gunawardana, M Remedios-Chan, CS Miller, R Fanter, F Yang, ...
Antimicrobial agents and chemotherapy 59 (7), 3913-3919, 2015
Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)
CW Hendrix, A Andrade, NN Bumpus, AD Kashuba, MA Marzinke, ...
AIDS research and human retroviruses 32 (1), 32-43, 2016
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
RJ Landovitz, S Li, B Grinsztejn, H Dawood, AY Liu, M Magnus, ...
PLoS medicine 15 (11), e1002690, 2018
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single-or dual-agent preexposure prophylaxis
DA Lehman, JM Baeten, CO McCoy, JF Weis, D Peterson, G Mbara, ...
The Journal of infectious diseases 211 (8), 1211-1218, 2015
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind …
JM Baeten, D Donnell, NR Mugo, P Ndase, KK Thomas, JD Campbell, ...
The Lancet infectious diseases 14 (11), 1055-1064, 2014
Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial
BA Chen, L Panther, MA Marzinke, CW Hendrix, CJ Hoesley, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 70 (3), 242-249, 2015
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
RJ Landovitz, S Li, JJ Eron, B Grinsztejn, H Dawood, AY Liu, M Magnus, ...
The lancet HIV 7 (7), e472-e481, 2020
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
LG Bekker, S Roux, E Sebastien, N Yola, KR Amico, JP Hughes, ...
The lancet HIV 5 (2), e68-e78, 2018
Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
R Heffron, K Ngure, J Odoyo, N Bulya, E Tindimwebwa, T Hong, ...
Gates open research 1, 2017
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial
S Delany-Moretlwe, C Lombard, D Baron, LG Bekker, B Nkala, K Ahmed, ...
The Lancet infectious diseases 18 (11), 1241-1250, 2018
Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption
KK Mugwanya, CW Hendrix, NR Mugo, M Marzinke, ET Katabira, K Ngure, ...
PLoS medicine 13 (9), e1002132, 2016
Optimizing pre-exposure antiretroviral prophylaxis adherence in men who have sex with men: Results of a pilot randomized controlled trial of “Life-Steps for PrEP”
KH Mayer, SA Safren, SA Elsesser, C Psaros, JP Tinsley, M Marzinke, ...
AIDS and Behavior 21, 1350-1360, 2017
A phase 1 trial to assess the safety, acceptability, pharmacokinetics, and pharmacodynamics of a novel dapivirine vaginal film
KE Bunge, CS Dezzutti, LC Rohan, CW Hendrix, MA Marzinke, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 71 (5), 498-505, 2016
Renal function of participants in the Bangkok tenofovir study—Thailand, 2005–2012
M Martin, S Vanichseni, P Suntharasamai, U Sangkum, PA Mock, ...
Clinical infectious diseases 59 (5), 716-724, 2014
The system can't perform the operation now. Try again later.
Articles 1–20